SG11202005772YA - Mhc class i associated peptides for prevention and treatment of multiple flavi virus - Google Patents
Mhc class i associated peptides for prevention and treatment of multiple flavi virusInfo
- Publication number
- SG11202005772YA SG11202005772YA SG11202005772YA SG11202005772YA SG11202005772YA SG 11202005772Y A SG11202005772Y A SG 11202005772YA SG 11202005772Y A SG11202005772Y A SG 11202005772YA SG 11202005772Y A SG11202005772Y A SG 11202005772YA SG 11202005772Y A SG11202005772Y A SG 11202005772YA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- treatment
- mhc class
- associated peptides
- flavi virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862614375P | 2018-01-06 | 2018-01-06 | |
PCT/GB2019/050024 WO2019135086A1 (en) | 2018-01-06 | 2019-01-04 | Mhc class i associated peptides for prevention and treatment of multiple flavi virus |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005772YA true SG11202005772YA (en) | 2020-07-29 |
Family
ID=65234592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005772YA SG11202005772YA (en) | 2018-01-06 | 2019-01-04 | Mhc class i associated peptides for prevention and treatment of multiple flavi virus |
Country Status (11)
Country | Link |
---|---|
US (3) | US11690904B2 (en) |
EP (1) | EP3735269A1 (en) |
JP (1) | JP2021509400A (en) |
CN (1) | CN111565746A (en) |
AU (1) | AU2019205627B2 (en) |
BR (1) | BR112020012021A2 (en) |
MX (1) | MX2020006357A (en) |
PH (1) | PH12020500579A1 (en) |
SG (1) | SG11202005772YA (en) |
WO (1) | WO2019135086A1 (en) |
ZA (1) | ZA202003770B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019186199A1 (en) * | 2018-03-29 | 2019-10-03 | Emergex Vaccines Holding Limited | Vaccine compositions |
TW202043256A (en) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
CN114980920A (en) | 2019-11-18 | 2022-08-30 | 詹森生物科技公司 | Vaccine based on mutant CALR and JAK2 and uses thereof |
TW202144389A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in multiple myeloma and their uses |
TW202144388A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in ovarian cancer and their uses |
WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
WO2023069551A1 (en) * | 2021-10-20 | 2023-04-27 | The Regents Of The University Of California | Multi-epitope mrna sars-cov-2 vaccine for boosting immunity through the activation of cd4 and cd8 t cells as well as b lymphocytes |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
WO2005014627A1 (en) * | 2003-08-07 | 2005-02-17 | International Centre For Genetic Engineering And Biotechnology | Recombinant dengue multi epitope proteins as diagnostic intermediates |
EP1793863B1 (en) | 2004-10-01 | 2017-04-12 | Midatech Ltd. | Nanoparticles comprising antigens and adjuvants capable of stimulating t helper cells |
CA2617869C (en) | 2005-08-04 | 2017-02-14 | Thomas William Rademacher | Nanoparticles comprising antibacterial ligands |
AU2007242572B2 (en) | 2006-04-13 | 2011-11-24 | Midatech Limited | Nanoparticles containing three various ligands for providing immune responses against infectious agents |
US8512991B2 (en) * | 2007-08-22 | 2013-08-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use |
CA2802031C (en) * | 2010-06-10 | 2015-05-12 | Midatech Limited | Peptide-carrying nanoparticles |
BR112013032421A2 (en) * | 2011-06-29 | 2017-01-17 | Immunotope Inc | method for prophylaxis or treatment of a dengue virus infection, method for inducing a cytotoxic t-lymphocyte mediated immune response, dengue virus vaccine, method for preventing a dengue virus disease, and method for inducing an immune response to at least one dengue virus |
JP6077544B2 (en) | 2011-09-07 | 2017-02-08 | ミダテック リミテッド | Nanoparticle-peptide composition |
WO2013059403A1 (en) * | 2011-10-19 | 2013-04-25 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of influenza virus infection |
WO2015048149A1 (en) * | 2013-09-24 | 2015-04-02 | Massachusetts Institute Of Technology | Self-assembled nanoparticle vaccines |
WO2015175361A1 (en) * | 2014-05-13 | 2015-11-19 | Immunotope, Inc. | Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development |
WO2017015463A2 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Infectious disease vaccines |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
SG11201806340YA (en) | 2016-02-17 | 2018-09-27 | Curevac Ag | Zika virus vaccine |
WO2018218355A1 (en) * | 2017-05-30 | 2018-12-06 | Western University | Method of diagnosing flavivirus infection |
SG11202002044WA (en) | 2017-09-21 | 2020-04-29 | Emergex Vaccines Holding Ltd | MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus |
-
2019
- 2019-01-04 BR BR112020012021-9A patent/BR112020012021A2/en unknown
- 2019-01-04 WO PCT/GB2019/050024 patent/WO2019135086A1/en unknown
- 2019-01-04 US US16/957,931 patent/US11690904B2/en active Active
- 2019-01-04 EP EP19701899.7A patent/EP3735269A1/en active Pending
- 2019-01-04 CN CN201980006880.4A patent/CN111565746A/en active Pending
- 2019-01-04 MX MX2020006357A patent/MX2020006357A/en unknown
- 2019-01-04 AU AU2019205627A patent/AU2019205627B2/en active Active
- 2019-01-04 SG SG11202005772YA patent/SG11202005772YA/en unknown
- 2019-01-04 JP JP2020534924A patent/JP2021509400A/en active Pending
-
2020
- 2020-06-22 ZA ZA2020/03770A patent/ZA202003770B/en unknown
- 2020-07-02 PH PH12020500579A patent/PH12020500579A1/en unknown
-
2023
- 2023-06-09 US US18/332,022 patent/US20230346908A1/en active Pending
- 2023-10-13 US US18/486,459 patent/US20240050548A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3735269A1 (en) | 2020-11-11 |
US11690904B2 (en) | 2023-07-04 |
JP2021509400A (en) | 2021-03-25 |
US20230346908A1 (en) | 2023-11-02 |
MX2020006357A (en) | 2020-08-17 |
US20240050548A1 (en) | 2024-02-15 |
WO2019135086A1 (en) | 2019-07-11 |
PH12020500579A1 (en) | 2021-05-17 |
BR112020012021A2 (en) | 2020-12-22 |
CN111565746A (en) | 2020-08-21 |
AU2019205627B2 (en) | 2024-05-09 |
AU2019205627A1 (en) | 2020-06-11 |
US20210361760A1 (en) | 2021-11-25 |
ZA202003770B (en) | 2023-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202005772YA (en) | Mhc class i associated peptides for prevention and treatment of multiple flavi virus | |
IL277648A (en) | Therapeutic microbiota for the treatment and/or prevention of food allergy | |
HK1248546A1 (en) | Combination of wt1 antigen peptide and immunomodulator | |
IL281277A (en) | Compositions and methods for the treatment of viral infections | |
ZA201905851B (en) | Peptides and methods for the treatment of diabetes | |
IL263368A (en) | Prevention and treatment of viral infections | |
HK1251616A1 (en) | Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases | |
FI3773689T3 (en) | Antigenic peptides for prevention and treatment of cancer | |
SG11202002044WA (en) | MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus | |
SG11202104178TA (en) | Peptides and pharmaceutical compositions for treating eye diseases | |
IL284029B1 (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
IL282904A (en) | Therapeutic microbiota for the treatment and/or prevention of dysbiosis | |
GB201522329D0 (en) | Use of adjuvants for the prevention and/or treatment of autoimmune diseases | |
HUE049890T2 (en) | Recombinant lumpy skin disease virus knock-out mutant and uses thereof | |
DK3810128T3 (en) | COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF PROTEIN AGGREGATION DISEASES | |
EP3617222A4 (en) | Peptide for inducing regeneration of tissue, and use thereof | |
IL280450A (en) | Cdca1-derived peptide and vaccine containing same | |
RS65225B1 (en) | Medicament for the treatment and/or prevention of endometriosis | |
GB201820614D0 (en) | MHC Class I associated peptides for prevention and treatment of hepatitis B virus infection | |
EP4025585A4 (en) | Modified peptides and associated methods of use | |
EP3615551A4 (en) | Modified cyclic peptides and therapeutic use thereof | |
ZA201803649B (en) | Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases |